Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancer
Noninvasive circulating tumor DNA (ctDNA) can be used to predict breast cancer recurrence and prognosis. In this study, we detected 226 and 114 somatic variants in tumor DNA from 70 primary breast cancer (PBC) patients (98.59%) and ctDNA from 48 patients (67.61%), respectively. Gene frequencies of t...
Main Authors: | Yidong Zhou, Yaping Xu, Yuhua Gong, Yanyan Zhang, Yaping Lu, Changjun Wang, Ru Yao, Peng Li, Yanfang Guan, Jiayin Wang, Xuefeng Xia, Ling Yang, Xin Yi, Qiang Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-05-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12456 |
Similar Items
-
Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice
by: Robin Imperial, et al.
Published: (2019-09-01) -
The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
by: Sakti Chakrabarti, et al.
Published: (2020-09-01) -
ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC)
by: Laura Masfarré, et al.
Published: (2021-06-01) -
Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA)
by: Minji Lim, et al.
Published: (2018-02-01) -
Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer
by: Elisa Gobbini, et al.
Published: (2020-10-01)